Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March). This quarter, 6 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from China, two from the EU, and one from Australia:
Vilobelimab (Gohibic)
Garadacimab (Andembry)
Finotonlimab (新替妥)
Siltartoxatug (Sintetol)
Sipavibart (Kavigale)
Teprotumumab N01 (Sycume)
Q1 2025 saw several large collaborations and acquisitions of up to USD$3.1 billion in value. The majority of collaborative efforts focused on developing novel platforms such as bispecific antibody and ADC engineering.
Gain exclusive insights into current trends such as:
6 novel antibody drugs approved for the first time in Q1
Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$3.1B
Novel platforms such as bispecific antibody and ADC engineering
Recent research into obesity and COVID-19 treatments
A list of antibody drugs in regulatory review to keep an eye out for in Q2 2025
